Published in Xenobiotica on September 01, 2004
Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol (2009) 0.91
Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not. Eur J Clin Pharmacol (2006) 0.86
Pharmacogenetics of anticoagulants. Hum Genomics Proteomics (2010) 0.84
Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics (2011) 0.83
VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. Eur J Clin Pharmacol (2010) 0.83
CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis. J Mol Model (2011) 0.75
Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. Eur J Clin Pharmacol (2009) 0.75
Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ (2000) 8.10
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet (1997) 3.08
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry (2004) 2.98
Yeast regulatory gene PPR1. I. Nucleotide sequence, restriction map and codon usage. J Mol Biol (1984) 2.66
Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol (1999) 2.57
Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther (1971) 2.45
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics (2001) 2.21
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther (2009) 2.19
Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr (1982) 2.07
Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther (1999) 1.96
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet (1995) 1.79
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol (1999) 1.76
A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res (1996) 1.74
A new class of plastidic phosphate translocators: a putative link between primary and secondary metabolism by the phosphoenolpyruvate/phosphate antiporter. Plant Cell (1997) 1.66
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med (2000) 1.57
Acetaminophen: potentially toxic metabolite formed by human fetal and adult liver microsomes and isolated fetal liver cells. Science (1979) 1.54
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J (2006) 1.53
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J (2005) 1.53
Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics (2000) 1.52
Clinical pharmacokinetics in infants and children. Clin Pharmacokinet (1976) 1.49
Lamotrigine and toxic epidermal necrolysis. Lancet (1996) 1.48
Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther (1997) 1.48
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J (2003) 1.44
Morphine metabolism in children. Br J Clin Pharmacol (1989) 1.44
Therapeutic drug monitoring of anticonvulsants. State of the art. Clin Pharmacokinet (1990) 1.42
Early onset discordant growth in a successful monochorionic twin pregnancy. BJOG (2002) 1.39
Immunosuppressive properties of cyclosporin metabolites. Lancet (1989) 1.39
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther (2010) 1.38
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther (1978) 1.33
Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence. Br J Clin Pharmacol (1983) 1.33
Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther (1985) 1.30
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther (2007) 1.29
Complete sequence of a eukaryotic regulatory gene. EMBO J (1983) 1.28
Expression of the functional mature chloroplast triose phosphate translocator in yeast internal membranes and purification of the histidine-tagged protein by a single metal-affinity chromatography step. Proc Natl Acad Sci U S A (1993) 1.28
Structural organization of pLP1, a cryptic plasmid from Lactobacillus plantarum CCM 1904. Plasmid (1989) 1.26
Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol (1979) 1.25
Morphine glucuronidation in human fetal and adult liver. Eur J Clin Pharmacol (1982) 1.24
Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. Br J Clin Pharmacol (1985) 1.23
Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther (1999) 1.23
Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther (1992) 1.22
The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J (2007) 1.21
Prednisolone excretion in human milk. J Pediatr (1985) 1.19
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol (2001) 1.17
Kinetics of carbamazepine and its 10,11-epoxide metabolite in children. Clin Pharmacol Ther (1976) 1.15
Yeast regulatory gene PPR1. II. Chromosomal localization, meiotic map, suppressibility, dominance/recessivity and dosage effect. J Mol Biol (1984) 1.13
Structure and organisation of the pyrimidine biosynthesis pathway genes in Lactobacillus plantarum: a PCR strategy for sequencing without cloning. Gene (1996) 1.13
Morphine kinetics in cancer patients. Clin Pharmacol Ther (1981) 1.12
The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol (1990) 1.11
Cloning and analysis of the gene for the major outer membrane lipoprotein from Pseudomonas aeruginosa. Mol Microbiol (1989) 1.10
Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther (1978) 1.10
Placental passage of oxazepam and its metabolism in mother and newborn. Clin Pharmacol Ther (1979) 1.09
Comment on Stanford et al.: Traditional native tissue vs mesh-augmented pelvic organ prolapse repairs: providing an accurate interpretation of current literature. Int Urogynecol J (2012) 1.09
Arylamine N-acetyltransferase activity in man. Drug Metab Rev (1999) 1.09
Steady-state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol (1983) 1.08
Short term urinary catheter policies following urogenital surgery in adults. Cochrane Database Syst Rev (2006) 1.08
[The value of pharmacogenetic tests in antidepressive medication therapy]. Nervenarzt (2005) 1.07
Acetyltransferase in humans: development and tissue distribution. Pharmacology (1986) 1.06
The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J (2001) 1.05
Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res (2001) 1.05
Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther (2000) 1.04
Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics (1999) 1.03
Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol (1994) 1.03
Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase gene. Cancer Res (2000) 1.03
Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J (2007) 1.03
Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther (1977) 1.01
Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis (1997) 1.01
Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J (2010) 1.01
Loading and conventional dose therapy with phenytoin in children: kinetic profile of parent drug and main metabolite in plasma. Clin Pharmacol Ther (1976) 1.01
Determination of chromosome size and number of rrn loci in Lactobacillus plantarum by pulsed-field gel electrophoresis. FEMS Microbiol Lett (1994) 1.01
Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol (1999) 1.00
Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol (2002) 1.00
Valpromide/carbamazepine and risk of teratogenicity. Lancet (1985) 0.99
Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. J Pediatr (1971) 0.99
Comparative assessment of pelvic floor strength using a perineometer and digital examination. BJOG (2000) 0.98
Glucuronidation of morphine in human liver and interaction with oxazepam. Acta Anaesthesiol Scand Suppl (1982) 0.98
A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet (1997) 0.97
Thyroid function and pregnancy: before, during and beyond. J Obstet Gynaecol (2010) 0.97
Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther (1980) 0.97
High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes. Pharmacogenetics (1998) 0.97
Prenatal and neonatal drug metabolism in man. Eur J Clin Pharmacol (1980) 0.96
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology (2003) 0.96
Cyclosporin metabolites and central-nervous-system toxicity. Lancet (1988) 0.96
Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'-flanking region. Clin Investig (1994) 0.96
Human and rodent type 1 11beta-hydroxysteroid dehydrogenases are 7beta-hydroxycholesterol dehydrogenases involved in oxysterol metabolism. Cell Mol Life Sci (2004) 0.96
Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1). Biochem Pharmacol (1998) 0.95
Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression. Life Sci (2000) 0.95
Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur J Clin Pharmacol (1974) 0.95
Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther (2011) 0.95
Two distinct forms of glutathione transferase from human foetal liver. Purification and comparison with isoenzymes isolated from adult liver and placenta. Biochem J (1986) 0.94
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol (2005) 0.94
Inhibition of morphine glucuronidation by oxazepam in human fetal liver microsomes. Drug Metab Dispos (1982) 0.94